(2025). Evaluation of Serum Chromogranin A as an Early Marker of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus. The Egyptian Journal of Hospital Medicine, 98(1), 128-134. doi: 10.21608/ejhm.2025.402417
. "Evaluation of Serum Chromogranin A as an Early Marker of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus". The Egyptian Journal of Hospital Medicine, 98, 1, 2025, 128-134. doi: 10.21608/ejhm.2025.402417
(2025). 'Evaluation of Serum Chromogranin A as an Early Marker of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus', The Egyptian Journal of Hospital Medicine, 98(1), pp. 128-134. doi: 10.21608/ejhm.2025.402417
Evaluation of Serum Chromogranin A as an Early Marker of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus. The Egyptian Journal of Hospital Medicine, 2025; 98(1): 128-134. doi: 10.21608/ejhm.2025.402417
Evaluation of Serum Chromogranin A as an Early Marker of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus
Background: Diabetic nephropathy (DN) is a significant complication of type 2 diabetes mellitus (T2DM), resulting in end-stage renal failure and chronic kidney disease. Current diagnostic methods, primarily based on microalbuminuria, have limitations, as renal function may decline before its onset. Chromogranin A (CgA), a neuroendocrine protein cleared by the kidney, was proposed as a potential early biomarker for DN. Objective: This research evaluates serum CgA levels in relation to different stages of albuminuria and its diagnostic utility in initial identification of DN. Subjects and methods: This case-control research comprised 80 patients split up into 4 groups: T2DM with normoalbuminuria (n=20), microalbuminuria (n=20), macroalbuminuria (n=20), and healthy controls (n=20). Serum CgA was determined utilizing enzyme-linked immunosorbent assay (ELISA). Other parameters comprised eGFR, serum creatinine, lipid profile, HbA1c, and fasting plasma glucose (FPG). Diagnostic accuracy was ascertained utilizing receiver operating characteristic (ROC) curve analysis. Results: Serum CgA levels were significantly elevated in macroalbuminuria (1606.8 ± 868.9 ng/L), microalbuminuria (706.7 ± 213.2 ng/L), and normoalbuminuria (557.6 ± 94.1 ng/L) compared to controls (500.5 ± 56.3 ng/L) (p < 0.001). CgA positively connected to albumin-creatinine ratio (r = 0.507, p < 0.001) and negatively with eGFR (r = -0.317, p=0.005). ROC analysis showed CgA had a sensitivity of 85.0% and specificity of 75.0% at a cutoff of 610 ng/L for detecting albuminuria (AUC=0.853, p < 0.001). Conclusions: Serum CgA is a promising biomarker for initial identification of DN, showing significant associations with albuminuria and renal function decline. Incorporating CgA into clinical practice may enhance early diagnosis and intervention in DN.
View on SCiNiTO
Top